secwatch / observer
8-K filed January 8, 2024, 6:59 PM ET ticker SLS CIK 0001390478
other material confidence high sentiment neutral materiality 0.75

SELLAS Life Sciences prices $9.0M public offering of 12M shares and warrants at $0.75/unit

SELLAS Life Sciences Group, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreements with certain investors (the "Purchasers") valued at approximately $9.0 million (effective 2024-01-04).

Action
entry
Agreement
equity purchase
Counterparty
certain investors (the "Purchasers")
Value
approximately $9.0 million
Effective
2024-01-04
Exact text from the filing
On January 4, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain investors (the “Purchasers).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (the "Placement Agent") (effective 2024-01-04).

Action
entry
Agreement
underwriting
Counterparty
A.G.P./Alliance Global Partners (the "Placement Agent")
Effective
2024-01-04
Exact text from the filing
On January 4, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company engaged the Placement Agent as the exclusive placement agent in connection with the Offering.
View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-24-002295
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.